Of 57 individuals diagnosed with Alzheimer’s disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
2.
GrundmanM, PontecorvoMJ, SallowaySP, DoraiswamyPM, FleisherAS, SadowskyCH, NairAK, SiderowfA, LuM, AroraAK, AgbulosA, FlitterML, KrautkramerMJ, SarsourK, SkovronskyDM, MintunMA (2013) Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord27, 4–15.
3.
KraemerS, Dell’AgnelloG, PontecorvoMJ, SiderowfA, LuM, HunterC, AroraAK, MintunM (2015) Potential effect of amyloid imaging on diagnosis and intended management of patients with cognitive decline: Impact of appropriate use criterion. Presented at the Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Berlin, Germany (Poster P016).
LandauSM, HorngA, FeroA, JagustWJ (2016) Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology86, 1377–1385.
6.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
7.
SeibylJ, CatafauAM, BarthelH, IshiiK, RoweCC, LeverenzJB, GhettiB, IronsideJW, TakaoM, AkatsuH, MurayamaS, BullichS, MuellerA, KoglinN, Schulz-SchaefferWJ, HoffmannA, SabbaghMN, StephensAW, SabriO (2016) Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: Results from a Phase 3 trial. J Nucl Med57, 900–906.
8.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association.. Alzheimers Dement9, e–16.
9.
GauglerJE, Ascher-SvanumH, RothDL, FafoworaT, SiderowfA, BeachTG (2013) Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: An analysis of the NACC-UDS database. BMC Geriatr13, 137.
10.
JackCRJr, KnopmanDS, ChetelatG, DicksonD, FaganAM, FrisoniGB, JagustW, MorminoEC, PetersenRC, SperlingRA, van der FlierWM, VillemagneVL, VisserPJ, VosSJ (2016) Suspected non-Alzheimer disease pathophysiology - concept and controversy. Nat Rev Neurol12, 117–124.
